Diabetes pill rybelsus tested in everyday life: does it really work?

NCT ID NCT05443334

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in real-world clinics across Spain. Researchers tracked changes in blood sugar (HbA1c), body weight, and how satisfied patients were with their treatment over 8-10 months. The goal was to see if the drug performs as well outside of strict clinical trials as it does in them.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (oral tablet, brand name Rybelsus)
What this could lead to: If successful, this study could confirm that oral semaglutide helps manage blood sugar and weight in real-world settings, supporting its routine use for type 2 diabetes.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It also does not test new uses or long-term safety beyond what is already known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Master Centre for Spain

Barcelona, 08025, Spain
Master Centre for Spain

Madrid, 28033, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.